Vevo Therapeutics is a biotechnology company using its in vivo drug discovery platform and next generation AI models to uncover better drugs for more patients. The company’s Mosaic platform is the first to make in vivo data generation scalable, with single-cell precision, to capture in vivo context of disease at the first step of drug discovery and to better represent patient diversity in drug response over current in vitro assays. Vevo is using Mosaic to build the world’s largest in vivo atlas of how drugs interact with patient cells and training AI models on its data to find novel targets and drugs undetectable by other technologies. Located in San Francisco, CA, Vevo was founded by a team of inventors and thought leaders who have discovered drugs for “undruggable” targets and invented novel methods in genomics, computational biology, and chemistry. Vevo is backed by leading investors at the intersection of life sciences and technology, including General Catalyst, Wing Venture Capital, Mubadala Capital, AIX Ventures, and Camford Capital. Learn more at www.vevo.ai.
External link for Vevo Therapeutics
Vevo 💛 Amazon Web Services (AWS)
Last year, we were one of the 20 startups (of 1200+) that were selected to be part of Amazon Web Services (AWS)'s Generative AI startup cohort. This year, we are excited to support AWS in welcoming more startups to the group. Thanks for the shout-out from our friends at AWS in this exciting announcement!
Vevo Therapeutics reposted this
Thank you to our AIX Ventures Fund I LPs, portfolio founders, and community for coming out to our Annual General Meeting over the weekend! Co-hosted by AIX Ventures co-founders, Shaun Johnson and Richard Socher, our AGM included thoughts on the state of AI investing from AIX Investment Partners Richard Socher, Anthony Goldbloom, Christopher Manning, and Pieter Abbeel. They covered topics ranging from how we got to ChatGPT from a research perspective to how AI will impact the physical world and enterprises. Special thanks to AIX portfolio founders Nima Alidoust of Vevo Therapeutics, Nancy Xu of Moonhub, Jeff Huber of Chroma, and Edward Mehr of Machina Labs for sharing their founder journey and vertical insights on drug discovery, recruiting, open source adoption, and manufacturing, respectively. #ai #venturecapital #thoughtleadership
Vevo Therapeutics reposted this
I am fortunate that my job allows me to interact with the founders of some of the world’s most innovative Healthcare & Life Sciences startups on a daily basis. I recently got to chat with leaders from two of the startups accepted into the Amazon Web Services (AWS) Generative AI Accelerator - Vevo Therapeutics and Nosis Bio to find out how they are working to change the pharma R&D paradigm with GenAI and filter out the hype from the hope in this fast-evolving field. Take a look at our Executive Conversation, out now on the AWS Industry Blog: https://lnkd.in/eqzZZUqN #drugdiscovery #machinelearning #generativeai #genai #randd #pharma #startups #innovation Nima Alidoust Johnny Yu Jim Martineau Seth Myers Eric Zimmerman
Vevo Therapeutics reposted this
I am fortunate that my job allows me to interact with the founders of some of the world’s most innovative Healthcare & Life Sciences startups on a daily basis. I recently got to chat with leaders from two of the startups accepted into the Amazon Web Services (AWS) Generative AI Accelerator - Vevo Therapeutics and Nosis Bio to find out how they are working to change the pharma R&D paradigm with GenAI and filter out the hype from the hope in this fast-evolving field. Take a look at our Executive Conversation, out now on the AWS Industry Blog: https://lnkd.in/eqzZZUqN #drugdiscovery #machinelearning #generativeai #genai #randd #pharma #startups #innovation Nima Alidoust Johnny Yu Jim Martineau Seth Myers Eric Zimmerman